News Jun 20, 2014 Stemedica plans to initiate Phase IIa 70-patient Alzheimer’s disease trial this year – executive Another Stemedica subsidiary, CardioCell, has an exclusive, worldwide license for IV-administered allogeneic ischemia-tolerant mesenchymal stem cells (itMSCs).
Read MoreStem cell trial is approved for patients with heart failure
News Apr 5, 2014 Stem cell trial is approved for patients with heart failure CardioCell has received approval from the FDA for a Phase IIa clinical trial of its allogeneic stem cell therapy for chronic heart failure. READ FULL ARTICLE
Read MoreFDA Approves CardioCell’s Phase 2A Trial For CHF Stem Cell Therapy
News Apr 4, 2014 FDA Approves CardioCell's Phase 2A Trial For CHF Stem Cell Therapy CardioCell LLC announced that it has received FDA approval for its investigational new drug (IND) application for a U.S.-based Phase IIA clinical study evaluating its allogeneic stem-cell therapy for
Read MoreCardioCell to scout for CROs for PAD trial with allogeneic mesenchymal stem cells, in partnership talks – CEO
News Apr 4, 2014 CardioCell to scout for CROs for PAD trial with allogeneic mesenchymal stem cells, in partnership talks –
Read MoreCardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure
News Apr 3, 2014 CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure CardioCell LLC has just received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell
Read MoreFDA grants IND approval for CardioCell’s phase IIa itMSC Therapy trial
News Apr 2, 2014 FDA grants IND approval for CardioCell’s phase IIa itMSC Therapy trial CardioCell, a global biotechnology company, has just received the FDA’s Investigational New Drug (IND) approval for a U.S.-based, phase IIa clinical study using its allogeneic stem-cell therapy to
Read MoreFDA Gives Go-Ahead for Phase 2a Trial of CardioCell CHF Stem Cell Therapy
News Apr 2, 2014 FFDA Gives Go-Ahead for Phase 2a Trial of CardioCell CHF Stem Cell Therapy CardioCell LLC has just received the FDA’s investigational new drug (IND) approval for a United States-based, Phase 2a clinical study using its allogeneic stem-cell therapy to treat subjects
Read MoreCardioCell gets IND approval from FDA
News Apr 2, 2014 CardioCell gets IND approval from FDA San Diego-based CardioCell LLC on Wednesday received the Food and Drug Administration’s investigational new drug (IND) approval for a phase 2a clinical study using its allogeneic stem-cell therapy to treat subjects with chronic
Read More